Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

29. August 2018 16:05 ET | Quelle: Krystal Biotech, Inc.

Krystal Biotech to Present at Upcoming B. Riley FBR and H.C. Wainwright Healthcare Investor Conferences

PITTSBURGH, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients...
23. August 2018 08:00 ET | Quelle: Krystal Biotech, Inc.

Krystal Biotechs’ KB105 Receives Rare Pediatric Disease Designation from the FDA to Treat Patients with TGM-1-deficient Autosomal Recessive Congenital Ichthyosis

KB105 is Krystal’s second "off-the-shelf" topical gene therapy candidate to receive Rare Pediatric Disease Designation for treating debilitating skin diseases PITTSBURGH, Aug. 23, 2018 (GLOBE...
16. August 2018 19:17 ET | Quelle: Krystal Biotech, Inc.

Krystal Biotech Announces $10 Million Private Placement with Frazier Healthcare Partners

PITTSBURGH, Aug. 16, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (Nasdaq: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from...
09. August 2018 08:00 ET | Quelle: Krystal Biotech, Inc.

Krystal Biotech’s KB105 Granted Orphan Drug Designation by the FDA to Treat Patients With TGM-1 Deficient Autosomal Recessive Congenital Ichthyosis

PITTSBURGH, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (Nasdaq:KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from...
06. August 2018 08:00 ET | Quelle: Krystal Biotech, Inc.

Krystal Biotech Reports Second Quarter 2018 Financial Results and Provides Corporate Update

First two patients enrolled in Phase 1/2 clinical study of KB103, a first-in-class topical gene therapy for the treatment of dystrophic epidermolysis bullosa. PITTSBURGH, Aug. 06, 2018 (GLOBE...
16. Juli 2018 08:00 ET | Quelle: Krystal Biotech, Inc.

Krystal Biotech to Present Update on KB103 Program for Treatment of Dystrophic Epidermolysis Bullosa at debra Care Conference 2018

PITTSBURGH, July 16, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ:KRYS), a gene therapy company developing topical and intradermal “off-the-shelf” treatments for rare...
24. Mai 2018 08:00 ET | Quelle: Krystal Biotech, Inc.

U.S. FDA Grants Fast Track Designation for Krystal Biotech’s KB103 for the Treatment of Dystrophic Epidermolysis Bullosa

PITTSBURGH, May 24, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ:KRYS), a gene therapy company developing topical and intradermal "off-the-shelf" treatments for rare...
10. Mai 2018 09:18 ET | Quelle: Krystal Biotech, Inc.

Krystal Biotech Announces Dosing of First Patient in the Phase 1/2 trial of KB103, a First-in-Class Topical Gene Therapy for the Treatment of Dystrophic Epidermolysis Bullosa

PITTSBURGH, May 10, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ:KRYS), a gene therapy company developing topical and intradermal "off-the-shelf" treatments for rare...
09. Mai 2018 08:00 ET | Quelle: Krystal Biotech, Inc.

Krystal Biotech Presents In Vivo KB103 Data at the International Investigative Dermatology Conference that Show Human COL7 Incorporating into Anchoring Fibrils with Proper Structural Orientation

Lead product candidate, KB103, shown to successfully transfer COL7A1 gene and to correct recessive dystrophic epidermolysis bullosa (RDEB) PITTSBURGH, May 09, 2018 (GLOBE NEWSWIRE) -- Krystal...
07. Mai 2018 08:00 ET | Quelle: Krystal Biotech, Inc.

Krystal Biotech Reports First Quarter 2018 Financial Results and Provides Corporate Update

IND for KB103 to treat dystrophic epidermolysis bullosa (DEB) cleared by FDA Patient enrollment in Phase 1/2 study of KB103 to begin in May 2018 at Stanford University Krystal Biotech’s KB103...

Vorherige Seite